跳到正文
原文
The Lancet Gastroenterology & Hepatology· Masatoshi Kudo, Sadahisa Ogasawara, Ruibao Liu, Shanzhi Gu, Kunyuan Wang, Ming Zhao, Hongtao Hu, Zhaoyu Liu, Kecan Lin, Jingfeng Liu, Zhengyu Lin, Yonghong Zhang, Tao Peng, Jinhua Song, Makoto Ueno, Jiye Zhu, Lidan Bai, Lin Tong, Yanjun Shi, Guohong Han, Jiahong Dong·· 2026-08-26精选AI 评分66

TALENTACE III 期:按需 TACE 联合 atezolizumab 与 bevacizumab 改善未经治疗肝细胞癌的 TACE-PFS

[Articles] On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

AI 导读

TALENTACE III 期试验显示,按需 TACE 联合 atezolizumab 与 bevacizumab 较单用按需 TACE 显著改善未经治疗肝细胞癌患者的 TACE-PFS。该研究为多中心、随机、开放标签设计,总生存随访仍在进行中。

推荐理由

III 期 TALENTACE 以 TACE-PFS 为主要终点,为未经治疗肝细胞癌的联合治疗策略提供了随机对照层面的比较。

来源:The Lancet Gastroenterology & Hepatology · thelancet.com